CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞和双特异性抗体治疗时代的髓外骨髓瘤
英文原题：Extramedullary myeloma in the era of CAR T-cell and bispecific antibody therapies.
查看英文原题
Extramedullary myeloma in the era of CAR T-cell and bispecific antibody therapies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
尽管过去十年多发性骨髓瘤的治疗取得了显著进展，当前未满足的需求仍包括持续预后较差的患者群体，如高危细胞遗传学、老年和虚弱患者、浆细胞白血病、中枢神经系统受累以及髓外疾病。尽管T细胞重定向疗法在晚期多发性骨髓瘤中显示出极好的疗效，但这些疗法克服高危疾病（如骨髓瘤中的髓外受累）的能力是一个备受关注的关键领域。在本综述中，我们试图审视当前可用的T细胞重定向疗法数据，包括已批准和在研的CAR-T 细胞和双特异性抗体疗法，对髓外多发性骨髓瘤患者结局的具体影响。
展开英文摘要原文
Despite the significant advancements in multiple myeloma therapy over the last decade, current unmet needs include populations of patients who continue to have inferior outcomes, such as those with high-risk cytogenetics, elderly and frail patients, plasma cell leukemia, central nervous system involvement, and extramedullary disease.
Though T-cell redirecting therapies have shown excellent efficacy in advanced multiple myeloma, the ability of these therapies to overcome high-risk disease such as extramedullary involvement in myeloma is an area of critical attention. In this review, we seek to examine the specific impact of currently available data of T-cell redirecting therapies, including approved and investigational chimeric antigen receptor T-cell and bispecific antibody therapies, on outcomes in patients with extramedullary myeloma.
论文信息
- 作者
- Sanchez L、Richard S
- 单位
- Division of Hematology and Medical Oncology, Multiple Myeloma Program, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: Larysa.sanchez@mssm.edu.United States
- 文献类型
- 综述
- 期刊
- Seminars in hematology2025 Feb
- 原文标识
- PubMed 40021425 · DOI 10.1053/j.seminhematol.2025.02.001